ZandCellZandCell
  • HOME
  • About
    • About
    • News Releases
  • Programs
  • Science
  • Apply
  • Contact
  • Login

    Lost your password?

  • 0
    Cart
  1. Home
  2. B. C. girl with leukemia seeks Christmas stem cell donor – DigitalJournal.com
  3. NEWS

NEWS

Vitamin C may encourage blood cancer stem cells to die – Science Daily

Continue reading

2017-08-18 Michael Zand NEWS

Dr. Black on Selecting Immunotherapy Agents in Bladder Cancer – OncLive

OncLiveDr. Black on Selecting Immunotherapy Agents in Bladder CancerOncLivePeter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses selecting … Continue reading

2017-08-18 Michael Zand NEWS

Special issue of Future Medicinal Chemistry explores immunotherapy edit article – EurekAlert (press release)

Special issue of Future Medicinal Chemistry explores immunotherapy edit articleEurekAlert (press release)The field of immunotherapy is moving forward at an unprecedented rate, and a range of therapeutic approaches are now used in clinical practice, oft… Continue reading

2017-08-18 Michael Zand NEWS

Cellectis Starts BPDCN Phase I Trial with Gene-Edited CAR-T Therapy – Genetic Engineering & Biotechnology News


Deccan Chronicle

Vitamin C may encourage blood cancer stem cells to die
Science Daily
Vitamin C may “tell” faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone Health, and published …
High dose injections of vitamin C could help to fight blood cancer and stop it from spreading, study claimsDaily Mail
Vitamin C could help to fight cancer, a study claimsExpress.co.uk
Vitamin C stops blood cancer in miceSBS
The Sun –PanARMENIAN.Net
all 12 news articles »
Continue reading

2017-08-18 Michael Zand NEWS

Special issue of Future Medicinal Chemistry explores immunotherapy edit article – EurekAlert (press release)

Special issue of Future Medicinal Chemistry explores immunotherapy edit articleEurekAlert (press release)The field of immunotherapy is moving forward at an unprecedented rate, and a range of therapeutic approaches are now used in clinical practice, oft… Continue reading

2017-08-18 Michael Zand NEWS

Former Hollywood Stuntman Raising $10000 For His Stem Cell Therapy – DNAinfo

Cellectis Starts BPDCN Phase I Trial with Gene-Edited CAR–T Therapy
Genetic Engineering & Biotechnology News
Cellectis reported that the first patient has been dosed in a Phase I clinical trial evaluating its TALEN® gene-edited CAR T-cell product UCART123 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The BPDCN study follows on from …

and more »

Continue reading

2017-08-18 Michael Zand NEWS

Small-cap focus: UK biotechs seek to prosper in immunotherapy – Financial Times

Financial TimesSmall-cap focus: UK biotechs seek to prosper in immunotherapyFinancial TimesBut whatever lies in store for the UK pharma group, biotech companies a fraction of its size are poised to reap significant rewards from cancer treatments, not l… Continue reading

2017-08-18 Michael Zand NEWS

Cellectis Starts BPDCN Phase I Trial with Gene Edited CAR-T Cell Therapy – Genetic Engineering & Biotechnology News (blog)


DNAinfo

Former Hollywood Stuntman Raising $10000 For His Stem Cell Therapy
DNAinfo
More than 5,000 liver transplants in the United States take place each year, according to the “Stem Cell Therapy for Liver Diseases,” a review article published in the Journal of Stem Cell Research and Therapy. About 20,000 people are waiting for a …
Stem Cell Therapy Educational SeminarsCheckbiotech.org (press release)
Plant Stem Cell Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016–2024Medgadget (blog)
Young Patient With Autism Improves After Stem Cell Therapy ProgramMENAFN.COM
WhaTech
all 8 news articles »
Continue reading

2017-08-18 Michael Zand NEWS
  • 1
  • …
  • 1,334
  • 1,335
  • 1,336
  • 1,337
  • 1,338
  • …
  • 3,595
Recent Posts
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Шведская компания ZandCell поставит 160 млн доз вакцины от COVID-19 в несколько стран мира 2021-07-22
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
About Us

ZandCell is a biotechnology company pioneering the advancements and therapeutic applications of Stem Cell Therapy. Our Technology is called “Regenerate”.

SiteLock
Contact Info
+1-702-425-9049
+46-736-779970
info@zandcell.com
Find us on map


Latest News
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Official PayPal Seal


© 2024 ZandCell. All Rights Reserved.
  • About
  • Programs
  • Science
  • Privacy Policy
  • Contact
  • RSS
  • Send us email
  • Follow us on Twitter
  • Follow us on Facebook
  • Follow Us on Linkedin
  • Call us via Skype
  • Follow Us on Instagram
  • Subscribe our YouTube Channel
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

Cellectis Starts BPDCN Phase I Trial with Gene Edited CAR–T Cell Therapy
Genetic Engineering & Biotechnology News (blog)
Cellectis reported that the first patient has been dosed in a Phase I clinical trial evaluating its TALEN® gene-edited CAR–T cell product UCART123 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The BPDCN study follows on from …